MDT

80.97

-2.28%↓

VEEV

202.49

-5.23%↓

A

99.41

-1.09%↓

HQY

75.23

-1.66%↓

PDCO

30.81

-0.42%↓

MDT

80.97

-2.28%↓

VEEV

202.49

-5.23%↓

A

99.41

-1.09%↓

HQY

75.23

-1.66%↓

PDCO

30.81

-0.42%↓

MDT

80.97

-2.28%↓

VEEV

202.49

-5.23%↓

A

99.41

-1.09%↓

HQY

75.23

-1.66%↓

PDCO

30.81

-0.42%↓

MDT

80.97

-2.28%↓

VEEV

202.49

-5.23%↓

A

99.41

-1.09%↓

HQY

75.23

-1.66%↓

PDCO

30.81

-0.42%↓

MDT

80.97

-2.28%↓

VEEV

202.49

-5.23%↓

A

99.41

-1.09%↓

HQY

75.23

-1.66%↓

PDCO

30.81

-0.42%↓

Search

Novo Nordisk A-S

Abrir

SetorSaúde

60.89 -2.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

60.61

Máximo

62.55

Indicadores-chave

By Trading Economics

Rendimento

929M

28B

Vendas

14B

86B

P/E

Médio do Setor

21.171

63.778

EPS

6.34

Rendimento de Dividendos

2.33

Margem de lucro

32.947

Funcionários

76,302

EBITDA

4.2B

40B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+63.34% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.33%

2.39%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

19B

305B

Abertura anterior

63.54

Fecho anterior

60.89

Sentimento de Notícias

By Acuity

41%

59%

110 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Novo Nordisk A-S Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

25 de fev. de 2025, 15:33 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5 de fev. de 2025, 11:53 UTC

Ganhos

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 de fev. de 2025, 08:19 UTC

Ganhos

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2 de abr. de 2025, 11:25 UTC

Conversa de Mercado

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2 de abr. de 2025, 09:27 UTC

Ações em Alta

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

31 de mar. de 2025, 12:49 UTC

Conversa de Mercado

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28 de mar. de 2025, 15:11 UTC

Conversa de Mercado

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27 de mar. de 2025, 13:45 UTC

Conversa de Mercado
Ganhos

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24 de mar. de 2025, 10:19 UTC

Conversa de Mercado

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24 de mar. de 2025, 09:08 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19 de mar. de 2025, 15:54 UTC

Principais Notícias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11 de mar. de 2025, 15:31 UTC

Conversa de Mercado

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11 de mar. de 2025, 14:58 UTC

Conversa de Mercado

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10 de fev. de 2025, 12:00 UTC

Principais Notícias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 de fev. de 2025, 10:30 UTC

Principais Notícias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 de fev. de 2025, 16:16 UTC

Principais Notícias
Ganhos

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 de fev. de 2025, 14:56 UTC

Ganhos

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 de fev. de 2025, 13:59 UTC

Ganhos

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 de fev. de 2025, 12:02 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 de fev. de 2025, 11:35 UTC

Conversa de Mercado
Ganhos

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 de fev. de 2025, 10:10 UTC

Ações em Alta

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 de fev. de 2025, 09:43 UTC

Ganhos

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 de fev. de 2025, 08:47 UTC

Conversa de Mercado
Ganhos

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 de fev. de 2025, 08:38 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 de fev. de 2025, 08:32 UTC

Ganhos

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 de fev. de 2025, 08:30 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 de fev. de 2025, 06:46 UTC

Ganhos

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 de fev. de 2025, 06:45 UTC

Ganhos

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

Comparação entre Pares

Variação de preço

Novo Nordisk A-S Previsão

Preço-alvo

By TipRanks

63.34% parte superior

Previsão para 12 meses

Média 102.17 USD  63.34%

Máximo 124 USD

Mínimo 90 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Novo Nordisk A-S - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

5

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 66.88Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

110 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.